Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (33 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 06 Feb 2018 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Mahindra Manulife Mid Cap Fund |
|---|---|
| 06 Feb 2018 | ₹100.00 |
| 24 Oct 2018 | ₹92.86 |
| 11 Jul 2019 | ₹97.65 |
| 26 Mar 2020 | ₹82.73 |
| 11 Dec 2020 | ₹120.41 |
| 28 Aug 2021 | ₹171.77 |
| 15 May 2022 | ₹150.88 |
| 29 Jan 2023 | ₹166.05 |
| 16 Oct 2023 | ₹209.29 |
| 02 Jul 2024 | ₹287.31 |
| 19 Mar 2025 | ₹250.26 |
| 03 Dec 2025 | ₹279.70 |
| 20 Aug 2026 | ₹292.87 |
| Metric | Mahindra Manulife · Regular · IDCW NAV ₹27.37 Very High risk ★★★★☆ | Category median Mid Cap Fund · 33 funds |
|---|---|---|
| +6.29% | +4.36% | |
| +14.76% | +14.16% | |
| +11.57% | +13.38% | |
| — | +7.79% | |
| +13.42% | +9.71% | |
| +12.24% | — | |
| +18.87% | +11.96% | |
| +18.06% | +10.86% | |
| — | +9.43% | |
| Risk | ||
| 17.67% | 17.59% | |
| 0.47 | 0.44 | |
| 0.61 | 0.61 | |
| -33.21% | -47.34% | |
| Nifty Midcap 150 | — | |
| -3.11% | -3.13% | |
| 0.99 | 0.97 | |
| 94.3% | 91.4% | |
| 108.8% | 102.1% | |
| 2.02% | 2.04% | |
| ₹4,747Cr | ₹9,315Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹1.00K | — | |
| 72% | 41% | |
| Manish Lodha · 5.7y | — | |
| 06 Feb 2018 | — | |
| 58 | — | |
| 26.0% | — | |
| 1.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.